On September 29, Iovance Biotherapeutics, Inc. rose 18.29% in regular trading, trading at $13.13/share, with turnover of approximately $53.86 million.

On the news front, the company raised its full-year revenue guidance to a range of $410 million to $420 million, a significant increase from the prior guidance of $350 million to $370 million, and above the FactSet consensus estimate of $402.8 million. The upward revision signals strengthening commercial momentum for its cell therapy portfolio.

The guidance raise follows a strong second-quarter performance, in which the company reported record quarterly revenue of approximately $99.3 million, while its per-share loss of $0.11 also came in better than market expectations of a $0.13 to $0.14 loss. Iovance Biotherapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing autologous tumor infiltrating lymphocyte-based cell therapies for metastatic melanoma and other solid tumor cancers, with its flagship product Amtagvi approved for adult patients with unresectable or metastatic melanoma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)